Aligos Therapeutics, Inc.
ALGS
Price:
$14.16
Market Cap:
$87.29M
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company also develops ALG-020572, an antisense oligonucleotide to prevent HBsAg translation and secretion; and ALG-055009, a small molecule THR-ß agonist that is in the Phase 1a/1b for the treatment of non-alcoholic steatohepatitis(NASH). In addition, i...[Read more]
Industry
Biotechnology
IPO Date
2020-10-16
Stock Exchange
NASDAQ
Ticker
ALGS
The ROE as of September 2024 (TTM) for Aligos Therapeutics, Inc. (ALGS) is -110.59%
According to Aligos Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is -110.59%. This represents a change of 288.13% compared to the average of -28.49% of the last 4 quarters.
Aligos Therapeutics, Inc. (ALGS) Historical ROE (quarterly & annually)
How has ALGS ROE performed in the past?
The mean historical ROE of Aligos Therapeutics, Inc. over the last ten years is -20.76%. The current -110.59% ROE has changed 432.66% with respect to the historical average. Over the past ten years (40 quarters), ALGS's ROE was at its highest in in the December 2019 quarter at 28.02%. The ROE was at its lowest in in the March 2024 quarter at -58.30%.
Average
-20.76%
Median
-59.40%
Minimum
-95.22%
Maximum
101.35%
Aligos Therapeutics, Inc. (ALGS) ROE by Quarter and Year
Discovering the peaks and valleys of Aligos Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 40.83%
Maximum Annual ROE = 101.35%
Minimum Annual Increase = -161.25%
Minimum Annual ROE = -95.22%
| Year | ROE | Change |
|---|---|---|
| 2023 | -95.22% | 3.01% |
| 2022 | -92.44% | 33.07% |
| 2021 | -69.47% | 40.83% |
| 2020 | -49.33% | -161.25% |
| 2019 | 80.54% | -20.53% |
Aligos Therapeutics, Inc. (ALGS) Average ROE
How has ALGS ROE performed in the past?
The current ROE of Aligos Therapeutics, Inc. (ALGS) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-85.71%
5-year avg
-45.18%
10-year avg
-20.76%
Aligos Therapeutics, Inc. (ALGS) ROE vs. Peers
How is ALGS’s ROE compared to its peers?
Aligos Therapeutics, Inc.’s ROE is greater than CytomX Therapeutics, Inc. (-27.44%), less than Spero Therapeutics, Inc. (20.70%), greater than Neoleukin Therapeutics, Inc. (-47.64%), greater than Instil Bio, Inc. (-55.57%), greater than NextCure, Inc. (-57.63%), greater than Assembly Biosciences, Inc. (-121.55%), greater than Achilles Therapeutics plc (-47.36%), greater than Nuvation Bio Inc. (-98.79%),
| Company | ROE | Market cap |
|---|---|---|
| -27.44% | $92.96M | |
| 20.70% | $72.43M | |
| -47.64% | $8.20M | |
| -55.57% | $429.91M | |
| -57.63% | $39.17M | |
| -121.55% | $115.30M | |
| -47.36% | $29.17M | |
| -98.79% | $719.91M |
Build a custom stock screener for Aligos Therapeutics, Inc. (ALGS) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Aligos Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Aligos Therapeutics, Inc. (ALGS) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Aligos Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Aligos Therapeutics, Inc.'s ROE?
How is the ROE calculated for Aligos Therapeutics, Inc. (ALGS)?
What is the highest ROE for Aligos Therapeutics, Inc. (ALGS)?
What is the 3-year average ROE for Aligos Therapeutics, Inc. (ALGS)?
What is the 5-year average ROE for Aligos Therapeutics, Inc. (ALGS)?
How does the current ROE for Aligos Therapeutics, Inc. (ALGS) compare to its historical average?